Novo Nordisk Sees 'Low Single-Digit' Hit from Canadian Generics

Novo Nordisk expects a "low single-digit" impact from generic semaglutide entering the Canadian market, executive vice president of international operations Emil Kongshøj Larsen told analysts on the company's earnings call this week [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

Savings card positioned as lead defence

Larsen said the "leading tactic" in Canada is Novo Nordisk's savings card, which has seen "very good uptake" for both Ozempic and Wegovy [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. The comments came days after Health Canada authorized a second generic semaglutide injection, filed by Canadian-based Apotex, on May 1, 2026 [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html].

65% price cut triggered by third generic

Larsen flagged a significant upcoming change: once three generic competitors are on the market, Canadian policy mandates a 65% price cut to Novo Nordisk's list price [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. Larsen said, "We know, sort of, the game there, and we are ready to play it, particularly with the savings card" [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

Health Canada said it is currently reviewing seven other generic semaglutide submissions from different companies and expects to make regulatory decisions in the coming weeks and months [Source: canada.ca/en/health-canada/news/2026/05/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so.html]. Each new authorization moves the market closer to the third-entrant threshold that triggers the mandated list-price reduction.

Canada as a test case

The first Canadian generic, from Indian drugmaker Dr. Reddy's Laboratories, was approved on April 28, 2026 [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. BMO Capital Markets analyst Evan Seigerman said in a note late last month that the two new Canadian generics likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Ozempic and Wegovy [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

Seigerman told Reuters that "Investors will follow the evolution of the market in Canada closely as a test case to see if and how generics can compete with branded peptides" [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]. The firm will look at "how quickly pricing compression and revenue erosion impact Ozempic in the market as a proxy for other future generic entries," Seigerman said [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html].

U.S. spillover seen as limited

The Canadian generics are only available in Canada and not the U.S. [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. Seigerman said Canadian generic entry is likely to remain a localized headwind, with strong U.S. intellectual property protections preventing meaningful spillover [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

Even so, Ozempic sales in the U.S. may be pressured by competition with Eli Lilly's Mounjaro [Source: cnbc.com/2026/05/07/healthy-returns-novo-nordisk-faces-ozempic-generics-in-canada-.html]. Novo Nordisk faces mounting sales pressure as Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, continue to gain market share [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/].

What it means for Canadian buyers

For now, branded products remain widely stocked at Canadian pharmacies. Patients tracking changes can monitor the generic semaglutide tracker for new approvals and use the insurance coverage checker to review plan eligibility. Additional background on dosing forms including Rybelsus is available in our FAQ.

This article is for informational purposes only and does not constitute medical advice.